Journal Article Review Epublish
PubMed: 40227716 DOI: 10.3390/cancers17071176
Single-Dose Radiation Therapy for Localized Prostate Cancer: Where Does the Evidence Lead?
Cancers (Basel) 17(7)
Authors: Salvatore Cozzi, Amina Lazrek, Giuseppe Rubini, Dino Rubini, Angela Sardaro, Sarah Houabes, Cecile Laude, Frederic Gassa, Lilia Bardoscia, Camille Roukoz
Affiliations
- Radiation Oncology Department, Centre Leon Berard, 69373 Lyon, France.
- Radiation Oncology Unit, International University Hospital Cheikh Zaid, Rabat 10000, Morocco.
- Section of Nuclear Medicine, Interdisciplinary Department of Medicine, University of Bari, 70124 Bari, Italy.
- Radiation Oncology Department, University of Bari "Aldo Moro", 70124 Bari, Italy.
- Radiation Oncology Unit, Portes de Provence Hospital Groupe, 26200 Montélimar, France.
- Radiation Oncology Unit, S. Luca Hospital, Healthcare Company Tuscany Nord Ovest, 55100 Lucca, Italy.
Abstract
Prostate cancer (PCa) remains the most prevalent cancer among men and the second leading cause of cancer-related deaths worldwide. Early diagnosis is crucial as it opens up various treatment options with curative intent. Recent advancements confirm that radiotherapy (RT), particularly through modern techniques like stereotactic body RT (SBRT) and single-dose RT (SDRT), is a safe and effective treatment for both localized and advanced PCa. This manuscript reviews the evolution and current state of primary prostate SDRT, focusing on its benefits and limitations. SDRT offers advantages such as reduced treatment time and enhanced patient convenience, showing promising efficacy and safety, especially for low- and intermediate-risk PCa. Challenges include controlling intrafraction variability and organ motion, as well as minimizing urethral toxicity. Next-generation imaging and MR-guided RT are improving treatment accuracy. While SDRT shows potential for cost-effective PCa treatment, further research is needed to address its limitations and refine its clinical application.
MeSH
Radiotherapy, Brachytherapy, Neoplasms, Prostate, Prostatic Neoplasms, Therapeutics